Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Stock Plunges By 25% After Setback

 
• By Andrew McConaghie
  
Bluebird bio
Bluebird Bio is in a race to market in sickle cell gene therapy with Vertex and CRISPR Therapeutics. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

More from Therapeutic Category